Literature DB >> 20562231

Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.

Jens Waldmann1, Volker Fendrich, Julia Holler, Malte Buchholz, Ernst Heinmöller, Peter Langer, Annette Ramaswamy, Birgit Samans, Martin K Walz, Matthias Rothmund, Detlef K Bartsch, Emily P Slater.   

Abstract

The diagnosis of a malignant pheochromocytoma (PC) can only be established by the presence of distant metastases, but a subset of apparently benign PCs develop metastases. We have employed a microarray analysis to identify a typical gene expression profile which distinguishes malignant from benign PC. Total RNA was isolated from fresh-frozen tissue of five benign and five malignant PCs. The reference consisted of laser microdissected tissue from normal adrenal medulla. After generating Cy3- and Cy5-fluorescently labeled cDNAs, F-chips containing 11 540 spots were hybridized. Data were analyzed with the IMAGENE 3.0 software. Gene expression levels were validated by real-time (RT)-PCR and immunohistochemistry (IHC). The analysis revealed a more than twofold difference in expression between benign and malignant PCs in 132 genes: 19 were up-regulated and 113 were down-regulated. Expression differences of six genes (calsequestrin, NNAT, neurogranin, secreted protein acidic and rich in cysteine (SPARC), EGR2, and MAOB) were confirmed by RT-PCR in 25 PCs. IHC for calsequestrin revealed an overexpression in malignant PCs (7/10 vs 1/10, P=0.03). Comparative analysis by microarray of all ten PCs (benign/malignant) versus normal adrenal medulla revealed a more than twofold expression difference in 455/539 and 491/671 genes respectively. Several of these genes are known to participate on adrenal tumorigenesis, potential tumor suppressor genes, and oncogenes. Comprehensive gene expression analysis of malignant and benign PCs revealed different gene profiles, which could be used to discriminate between malignant and benign PCs. Based on these findings, the strategy for further follow-up and treatment could be modified accordingly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562231     DOI: 10.1677/ERC-09-0118

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  15 in total

1.  Differential expression of estrogen receptor beta isoforms in prostate cancer through interplay between transcriptional and translational regulation.

Authors:  Ming-Tsung Lee; Bin Ouyang; Shuk-Mei Ho; Yuet-Kin Leung
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 2.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

Review 3.  Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.

Authors:  Susan Richter; Nan Qin; Karel Pacak; Graeme Eisenhofer
Journal:  Adv Pharmacol       Date:  2013

4.  Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.

Authors:  Graeme Eisenhofer; Jacques W M Lenders; Gabriele Siegert; Stefan R Bornstein; Peter Friberg; Dragana Milosevic; Massimo Mannelli; W Marston Linehan; Karen Adams; Henri J Timmers; Karel Pacak
Journal:  Eur J Cancer       Date:  2011-10-28       Impact factor: 9.162

Review 5.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 6.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

Review 7.  Pheochromocytoma: implications in tumorigenesis and the actual management.

Authors:  U Shah; A Giubellino; K Pacak
Journal:  Minerva Endocrinol       Date:  2012-06       Impact factor: 2.184

Review 8.  From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma.

Authors:  Alberto Cascón; Daniel A Tennant
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

9.  Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.

Authors:  Alessio Giubellino; Petra Bullova; Svenja Nölting; Hana Turkova; James F Powers; Qingsong Liu; Sylvie Guichard; Arthur S Tischler; Ashley B Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2013-01-10       Impact factor: 4.736

Review 10.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.